Porton Advanced Solutions Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
Porton Advanced Solutions General Information
Description
Developer of gene and cell therapy development and production, intended to accelerate the commercialization of gene and cell therapies. The company operates an integrated platform featuring proprietary upstream and downstream process development, analytical method validation, current good manufacturing practice production, quality control, and quality assurance, enabling biotechnology and pharmaceutical companies to transition biological products from discovery to commercial production.
Contact Information
Website
www.portonbio.comCorporate Office
- Building 3, Tengfei Innovation Park
- Number 388 Xinping Street
- Suzhou, Jiangsu 215121
- China
Corporate Office
- Building 3, Tengfei Innovation Park
- Number 388 Xinping Street
- Suzhou, Jiangsu 215121
- China
Porton Advanced Solutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 31-Jul-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 19-Aug-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 16-Apr-2021 | $61.1M | $61.1M | Completed | Generating Revenue |
Porton Advanced Solutions Patents
Porton Advanced Solutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11879139-B1 | Scalable methods for purification of recombinant viruses | Active | 20-Sep-2022 | ||
| WO-2022207003-A1 | Chimeric antigen receptors targeting albumin and their methods of uses | Inactive | 02-Apr-2021 | ||
| WO-2022048621-A1 | Compositions and methods to target anti-rh antibody | Inactive | 03-Sep-2020 | ||
| US-20230287097-A1 | Compositions and methods to target anti-tnf-alpha antibody | Pending | 16-Jul-2020 | ||
| WO-2022012610-A1 | Compositions and methods to target anti-tnf-alpha antibody | Inactive | 16-Jul-2020 | C07K16/241 |
Porton Advanced Solutions Signals
Porton Advanced Solutions Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| China Merchants Venture Capital | Corporate Venture Capital | Minority | ||
| Hainan Xinguoxing Private Equity Fund Management | Growth/Expansion | Minority | ||
| China Merchants Capital | Asset Manager | Minority | ||
| China Merchants Group | Holding Company | Minority | ||
| China Merchants Securities | Asset Manager | Minority |
Porton Advanced Solutions FAQs
-
When was Porton Advanced Solutions founded?
Porton Advanced Solutions was founded in 2018.
-
Where is Porton Advanced Solutions headquartered?
Porton Advanced Solutions is headquartered in Suzhou, China.
-
What is the size of Porton Advanced Solutions?
Porton Advanced Solutions has 66 total employees.
-
What industry is Porton Advanced Solutions in?
Porton Advanced Solutions’s primary industry is Drug Discovery.
-
Is Porton Advanced Solutions a private or public company?
Porton Advanced Solutions is a Private company.
-
What is Porton Advanced Solutions’s current revenue?
The current revenue for Porton Advanced Solutions is .
-
How much funding has Porton Advanced Solutions raised over time?
Porton Advanced Solutions has raised $138M.
-
Who are Porton Advanced Solutions’s investors?
China Merchants Venture Capital, Hainan Xinguoxing Private Equity Fund Management, China Merchants Capital, China Merchants Group, and China Merchants Securities are 5 of 14 investors who have invested in Porton Advanced Solutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process